文献速递皮肤肿瘤

血浆游离DNA浓度在黑色素瘤中的预测与预后意义

The predictive and prognostic significance of cell-free DNA concentration in melanoma.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2020-07-28

研究分析转移性黑色素瘤患者(发现队列n=20,扩展队列n=166)及健康供者(n=116)血浆样本,用Qubit®平台检测单链和双链DNA、DNA分光光度法和RNase P qPCR测量总游离DNA浓度。Qubit®双链DNA法最优,黑色素瘤患者cfDNA高于健康对照(AUC 72%)。基线高cfDNA与转移及更高AJCC分期相关(P<0.05),且与总生存期缩短相关:致癌突变患者HR 2.12(P=0.0008),野生型患者HR 5.55(P<0.0001)。

要点

  • Qubit®双链DNA法测得黑色素瘤患者血浆cfDNA高于健康对照,AUC 72%。
  • 基线高cfDNA与转移存在及更高AJCC分期相关(P<0.05)。
  • 高基线cfDNA提示总生存期缩短,致癌突变者HR 2.12,野生型者HR 5.55。

核心结论

  • 总cfDNA可作为黑色素瘤生物标志物,不依赖肿瘤基因型,可提供肿瘤负荷、进展风险和死亡风险信息。

研究设计与样本

  • 分析转移性黑色素瘤患者发现队列(n=20)和扩展队列(n=166)及健康供者(n=116)的血浆样本。
  • 用Qubit®平台单链和双链DNA检测、DNA分光光度法和RNase P qPCR测量总血浆cfDNA浓度。

主要发现

  • Qubit®双链DNA法为最优方法,黑色素瘤患者血浆cfDNA浓度高于健康对照(AUC 72%)。
  • 基线高cfDNA与转移存在及更高AJCC分期相关(P<0.05)。
  • 高基线cfDNA与致癌突变患者总生存期缩短相关(HR 2.12,P=0.0008)。
  • 高基线cfDNA与野生型患者总生存期缩短相关(HR 5.55,P<0.0001)。

关键数值与推荐

  • 建立cfDNA阈值用于风险分层。

临床怎么用

  • 总cfDNA检测可辅助评估黑色素瘤肿瘤负荷、进展风险和死亡风险,不受肿瘤基因型限制。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Melanoma is the leading cause of skin cancer-related deaths worldwide. While there have been significant improvements in the treatment of advanced melanoma in the past decade, biomarker development lagged behind. OBJECTIVES: The majority of liquid biopsy biomarkers rely on the analyses of oncogenic mutations; however, about 20% of melanoma patients are wild type. Therefore, validation of universal predictive and prognostic biomarkers is urgently needed. METHODS: We analysed plasma samples in a discovery cohort (n = 20) and expansion cohort (n = 166) of metastatic melanoma patients and healthy donors (n = 116). Total plasma circulating cell-free DNA (cfDNA) concentrations were measured on the Qubit® platform using assays for single-(ss) and double (ds)-stranded DNA, DNA spectrophotometry and RNase P qPCR. We explored the diagnostic, predictive and prognostic potential of cfDNA concentration by bio-statistical methods and established a cfDNA threshold for risk stratification. RESULTS: Our selected best method was Qubit® dsDNA assay which quantified higher plasma cfDNA concentrations in melanoma patients than in healthy controls (AUC 72%). Measurement of baseline cfDNA concentration revealed that high cfDNA was associated with presence of metastases and higher AJCC stage (P < 0.05). Furthermore, high baseline cfDNA was an indicator of shorter overall survival in patients with oncogenic mutations (HR 2.12, P = 0.0008), and in wild-type patients (HR 5.55, P < 0.0001). CONCLUSIONS: We provide evidence that total cfDNA can be used as a biomarker for melanoma irrespective of the tumour genotype and can provide information on tumour load, risk of progression and risk of death.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Váraljai R, Elouali S, Lueong SS, et al. The predictive and prognostic significance of cell-free DNA concentration in melanoma. J Eur Acad Dermatol Venereol. 2020. PMID: 32569440. doi:10.1111/jdv.16766

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。